Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423866 | 0.89 | CYP1A2 (0.44) | CRBNOR51E2ALDH1A1KMT2ATLR4 | |
| SCHEMBL7625438 | 0.87 | CYP1A2 (0.44) | CRBNOR51E2ALDH1A1KMT2ATLR4 | |
| SCHEMBL11727840 | 0.86 | CYP1A2 (0.42) | ALDH1A1KMT2ATLR4CYP2C9CCR2 | |
| SCHEMBL4414565 | 0.84 | CRBN (0.40) | CRBNOR51E2ALDH1A1FKBP5NOS3 | |
| SCHEMBL5502631 | 0.82 | CYP1A2 (0.37) | ALDH1A1KMT2AOPRL1OPRM1MAPT | |
| SCHEMBL11728621 | 0.80 | CRBN (0.33) | CRBNOR51E2FKBP5CCR2LMNA | |
| SCHEMBL25280759 | 0.76 | CRBN (0.40) | CRBNOR51E2FKBP5 | |
| SCHEMBL17834527 | 0.75 | TLR4 (0.39) | ALDH1A1KMT2ATLR4OPRL1OPRM1 | |
| SCHEMBL17968884 | 0.75 | TLR4 (0.39) | ALDH1A1KMT2ATLR4OPRL1OPRM1 | |
| SCHEMBL178387 | 0.74 | ALDH1A1 (0.41) | ALDH1A1KMT2ATLR4OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328916-B1 | FLAME-RESISTANT POLYAMIDE AS REACTION PRODUCT OF A LACTAM, AND METHOD FOR THE PRODUCTION AND USE THEREOF | DEUTSCHE INST FUER TEXTIL UND FASERFORSCHUNG DENKENDORF (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| US-6858044-B1 | Increasing the wet slippage properties of textiles material, and wet-acting lubricants for this purpose | CLARIANT FINANCE (BVI) LIMITED (VG) | 2005-02-22 | — | — | US | disclosed |
| EP-1218586-B1 | INCREASING THE WET SLIPPAGE PROPERTIES OF TEXTILE MATERIAL, AND WET-ACTING LUBRICANTS FOR THIS PURPOSE | CLARIANT FINANCE BVI LTD (VG) | 2004-12-22 | — | — | EP | disclosed |
| EP-1218586-A1 | INCREASING THE WET SLIPPAGE PROPERTIES OF TEXTILE MATERIAL, AND WET-ACTING LUBRICANTS FOR THIS PURPOSE | Clariant Finance (BVI) Limited (VG) | 2002-07-03 | — | — | EP | disclosed |
| EP-1094147-A1 | Enhancement of the wet sliding property of textile material and a wet sliding agent therefore | CLARIANT INTERNATIONAL LTD. (CH) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001021880-A1 | INCREASING THE WET SLIPPAGE PROPERTIES OF TEXTILE MATERIAL, AND WET-ACTING LUBRICANTS FOR THIS PURPOSE | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885ALDH1A1 1721/4885 |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | CRBN 973/4885OR51E2 983/4885ALDH1A1 1186/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885ALDH1A1 1721/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.